Subretinal bevacizumab detection after intravitreous injection in rabbits

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 3, 2008, Pages 1097-1100

  Dib, Eduardo ^a,b   Maia, Mauricio ^a   Longo Maugeri, Ieda Maria ^a   Martins, Maria Cristina ^a   Mussalem, Juliana Sekeres ^a   Squaiella, Carla Cristina ^a   Penha, Fernando M ^a   Magalhães Jr , Octaviano ^a   Rodrigues, Eduardo B ^a   Farah, Michel Eid ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Apartment 511 ^*  (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FORMALDEHYDE; PENTOBARBITAL; SODIUM CHLORIDE; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; AQUEOUS HUMOR; ARTICLE; CILIARY DISK; CONTROLLED STUDY; DRUG DETERMINATION; DRUG DIFFUSION; DRUG TISSUE LEVEL; ENUCLEATION; ENZYME IMMUNOASSAY; FEMALE; MICROSCOPY; NONHUMAN; PARACENTESIS; PRIORITY JOURNAL; RABBIT; RETINA; RETINA DETACHMENT; RETINA TEAR; SUBRETINAL FLUID; ANIMAL; BODY FLUID; DRUG ANTAGONISM; EXUDATE; INJECTION; METABOLISM; TISSUE DISTRIBUTION; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BODY FLUIDS; EXUDATES AND TRANSUDATES; FEMALE; INJECTIONS; RABBITS; RETINA; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 41949140094     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-1225     Document Type: Article

References (18)

1. Michels sS, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (avastin) therapy for neovascular agerelated macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005; 112:1035-1047.
2. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
3. Arnold J. Age related macular degeneration. Clin Evid 2006;877-888.
4. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol. 1999;117:1329-1345.
5. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchán I, Kelly SP. Smoking and age-related macular degeneration: a review of association. Eye. 2005;19:935-944.
6. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled openlabel clinical study. Ophthalmology. 2006;113:2002,E1-E12.
7. Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother. 2004;38:1258-1264.
8. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352:476-487.
9. Emmanouilides C, Pegram M, Robinson R, Hecht R, Kabbinavar F, Isacoff W. Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer. Tech Coloproctol. 2004;8(suppl)1:S50-S52.
10. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology. 2007;114:743-750.
11. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Ophthalmology. 2006;113:363-372.
12. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 1251-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27: 536-544.
13. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006;26:262-269.
14. Ivert L, Kjeldbye H, Gouras P. Long-term effects of short-term retinal bleb detachments in rabbits. Graefes Arch Clin Exp Ophthalmol. 2002;240:232-237.
15. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114: 855-859.
16. Coligan JE. Assays for antibody detection. Enzyme linked immunosorbent assays: direct ELISA. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, eds. Current Protocols in Immunology. Atlanta: Wiley; 1995:2-16.
17. Schuettauf F, Haritoglou C, May CA, et al. Administration of novel dyes for intraocular surgery: an in vivo toxicity animal study. Invest Ophthalmol Vis Sci. 2006;47:3573-3578.
18. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7:335-345.